SCHEMBL6737951

SCHEMBL6737951

O=C(NCCCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O)C(F)(F)F

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TK1 P04183 3/20 0.64
TK2 O00142 1/20 0.64
LMNA P02545 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
ALOX12 P18054 1/20 0.60
ADRA1A P35348 1/20 0.60
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
TSHR P16473 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6737955 1.00 TK1 (0.64) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL13412992 1.00 TK1 (0.64) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL8167217 0.96 TK1 (0.62) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL7877862 0.91 TK1 (0.58) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL7877854 0.91 TK1 (0.58) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL12060321 0.89 LMNA (0.64) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL13082855 0.89 LMNA (0.64) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL4061948 0.87 TK2 (0.49) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL1006890 0.87 TK1 (0.67) TK1TK2LMNASMN1; SMN2ALOX12
SCHEMBL1356100 0.87 TK1 (0.67) TK1TK2LMNASMN1; SMN2ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE38416-E1 NUCLEOTIDE BASES COMPRISING PYRAZOLO(3,4-D)PYRIMIDINES USED FOR MEDICAL DIAGNOSIS, THERAPY, HYBRIDIZATION, ANTISENSE AGENTS OR REPORTER MOLECULES EPOCH BIOSCIENCES, INC. 2004-02-03 US disclosed
US-6031086-A HAVING DIMINISHED CHARGE BUT UNDIMINISHED ABILITY TO COMPLEX WITH NATURAL DNA AT LOW IONIC STRENGTHS; PREPARED BY REPLACING NATURAL NUCLEOTIDES WITH UNNATURAL ZWITTERIONIC NUCLEOTIDES; MEMBRANE PERMEABLE AND NUCLEASE RESISTANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-02-29 US disclosed
US-5912340-A FORMING STABLE HYBRID WITH DNA, RNA EPOCH PHARMACEUTICALS, INC. (US) 1999-06-15 US disclosed
US-5849482-A Crosslinking oligonucleotides EPOCH PHARMACEUTICALS, INC. (US) 1998-12-15 US disclosed
US-5824796-A MEDICAL DIAGNOSIS WITH TARGET DNA OR RNA FOR ENZYME INHIBITORS EPOCH PHARMACEUTICALS, INC. (US) 1998-10-20 US disclosed
EP-0842186-A1 CROSS-LINKING OLIGONUCLEOTIDES MICROPROBE CORPORATION (US) 1998-05-20 EP disclosed
US-5596091-A DNA AND RNA FOR GENE EXPRESSION FOR DIAGNOSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-01-21 US disclosed
EP-0661979-A4 CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION. MICROPROBE CORP (US) 1995-09-13 EP disclosed
EP-0661979-A1 CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION MICROPROBE CORPORATION (US) 1995-07-12 EP disclosed
WO-1993003736-A1 CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION MICROPROBE CORPORATION (US) 1993-03-04 WO disclosed
EP-0472648-A4 CROSSLINKING OLIGONUCLEOTIDES 1992-09-16 EP disclosed
EP-0472648-A1 CROSSLINKING OLIGONUCLEOTIDES MICROPROBE CORPORATION (US) 1992-03-04 EP disclosed
WO-1990014353-A1 CROSSLINKING OLIGONUCLEOTIDES MICROPROBE CORPORATION (US) 1990-11-29 WO disclosed